Additionally, the 5 year AUC of LEP, DLX2, CLSTN2, and REG3A were 0.638, 0.622, 0.5, and 0.62, respectively (AUC < 0.65), indicating that the combined gene signature panel have better performance on evaluating the prognosis of COAD patients. Here, CLSTN2 is linked to colon adenocarcinoma.